株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の免疫治療薬市場:種類別、治療分野別、エンドユーザー別、地域別 - 世界市場の規模、シェア、発展、成長、需要予測

Immunotherapy Drugs Market by Type, by Therapy Area, by End User, by Geography - Global Market Size, Share, Development, Growth, and Demand Forecast, 2013-2023

発行 Prescient & Strategic Intelligence Private Limited 商品コード 783205
出版日 ページ情報 英文 207 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.68円で換算しております。
世界の免疫治療薬市場:種類別、治療分野別、エンドユーザー別、地域別 - 世界市場の規模、シェア、発展、成長、需要予測 Immunotherapy Drugs Market by Type, by Therapy Area, by End User, by Geography - Global Market Size, Share, Development, Growth, and Demand Forecast, 2013-2023
出版日: 2018年10月19日 ページ情報: 英文 207 Pages
概要

当レポートでは、世界の免疫治療薬市場について調査分析を行い、市場概要、市場動向などについて考察するとともに、種類別、治療分野別、エンドユーザー別、地域別に市場を分析、主な企業のプロファイルなどについて包括的にまとめています。

第1章 調査の背景

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 産業の考察

  • 疫学分析
  • 免疫治療薬の価格と償還シナリオ
  • 免疫治療薬の研究と資金調達の取り組み
  • パイプライン薬一覧
  • 治療プロトコルと治療の選択

第5章 イントロダクション

  • 市場セグメントの定義
  • 市場のダイナミクス
  • ファイブフォース分析

第6章 世界市場の規模と予測

  • 種類別
  • 治療分野別
  • エンドユーザー別
  • 地域別

第7章 北米市場の規模と予測

  • 種類別
  • 治療分野別
  • エンドユーザー別
  • 国別

第8章 欧州市場の規模と予測

  • 種類別
  • 治療分野別
  • エンドユーザー別
  • 国別

第9章 アジア太平洋地域市場の規模と予測

  • 種類別
  • 治療分野別
  • エンドユーザー別
  • 国別

第10章 ラテンアメリカ市場の規模と予測

  • 種類別
  • 治療分野別
  • エンドユーザー別
  • 国別

第11章 中東/アフリカ市場の規模と予測

  • 種類別
  • 治療分野別
  • エンドユーザー別
  • 国別

第12章 競合状況

  • 主要企業の製品シェア分析
  • 主要企業の世界戦略

第13章 企業プロファイル

  • Eli Lilly and Company
  • Sanofi
  • Novartis AG
  • AbbVie Inc.
  • Hoffmann-La Roche Ltd.
  • AstraZeneca PLC
  • Merck & Co. Inc.
  • GlaxoSmithKline plc
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • C. H. Boehringer Sohn AG & Co. KG
  • Celgene Corporation
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.

第14章 付録

図表

List of Tables

  • TABLE 1 ANALYSIS PERIOD OF THE STUDY
  • TABLE 2 IMMUNOTHERAPY PIPELINE DRUGS BY SANOFI
  • TABLE 3 IMMUNOTHERAPY PIPELINE DRUGS BY PFIZER INC.
  • TABLE 4 IMMUNOTHERAPY PIPELINE DRUGS BY NOVARTIS AG
  • TABLE 5 IMMUNOTHERAPY PIPELINE DRUGS BY MERCK & CO. INC.
  • TABLE 6 IMMUNOTHERAPY PIPELINE DRUGS BY JOHNSON & JOHNSON
  • TABLE 7 IMMUNOTHERAPY PIPELINE DRUGS BY GLAXOSMITHKLINE PLC
  • TABLE 8 IMMUNOTHERAPY PIPELINE DRUGS BY F. HOFFMAN-LA ROCHE LTD.
  • TABLE 9 IMMUNOTHERAPY PIPELINE DRUGS BY ELI LILLY AND COMPANY
  • TABLE 10 IMMUNOTHERAPY PIPELINE DRUGS BY CELGENE CORPORATION
  • TABLE 11 IMMUNOTHERAPY PIPELINE DRUGS BY C. H. BOEHRINGER SOHN AG & CO. KG
  • TABLE 12 IMMUNOTHERAPY PIPELINE DRUGS BY BRISTOL-MYERS SQUIBB COMPANY
  • TABLE 13 IMMUNOTHERAPY PIPELINE DRUGS BY ASTRAZENECA PLC
  • TABLE 14 IMMUNOTHERAPY PIPELINE DRUGS BY ABBVIE INC.
  • TABLE 15 SYSTEMIC THERAPY FOR METASTATIC OR UNRESECTABLE CANCER (MELANOMA)
  • TABLE 16 INTRAVENOUS IMMUNE GLOBULIN PRODUCTS LICENSED BY USFDA FOR THE TREATMENT OF INFECTIOUS DISEASES
  • TABLE 17 IMMUNOTHERAPEUTIC AGENTS UNDER CLINICAL STAGES FOR THE TREATMENT OF INFECTIOUS DISEASES
  • TABLE 18 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $B (2013-2017)
  • TABLE 19 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $B (2018-2023)
  • TABLE 20 GLOBAL IMMUNOTHERAPY CHECKPOINT INHIBITORS MARKET, BY BRAND, $B (2013-2017)
  • TABLE 21 GLOBAL IMMUNOTHERAPY CHECKPOINT INHIBITORS MARKET, BY BRAND, $B (2018-2023)
  • TABLE 22 GLOBAL IMMUNOTHERAPY VACCINES MARKET, BY TYPE, $B (2013-2017)
  • TABLE 23 GLOBAL IMMUNOTHERAPY VACCINES MARKET, BY TYPE, $B (2018-2023)
  • TABLE 24 GLOBAL IMMUNOTHERAPY VACCINES MARKET, BY BRAND, $B (2013-2017)
  • TABLE 25 GLOBAL IMMUNOTHERAPY VACCINES MARKET, BY BRAND, $B (2018-2023)
  • TABLE 26 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2017)
  • TABLE 27 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2018-2023)
  • TABLE 28 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2017)
  • TABLE 29 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2018-2023)
  • TABLE 30 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY REGION, $B (2013-2017)
  • TABLE 31 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY REGION, $B (2018-2023)
  • TABLE 32 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2017)
  • TABLE 33 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2018-2023)
  • TABLE 34 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2017)
  • TABLE 35 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2018-2023)
  • TABLE 36 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013-2017)
  • TABLE 37 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2018-2023)
  • TABLE 38 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2017)
  • TABLE 39 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2018-2023)
  • TABLE 40 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2017)
  • TABLE 41 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2018-2023)
  • TABLE 42 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013-2017)
  • TABLE 43 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2018-2023)
  • TABLE 44 APAC IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2017)
  • TABLE 45 APAC IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2018-2023)
  • TABLE 46 APAC IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2017)
  • TABLE 47 APAC IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2018-2023)
  • TABLE 48 APAC IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013-2017)
  • TABLE 49 APAC IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2018-2023)
  • TABLE 50 LATAM IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2017)
  • TABLE 51 LATAM IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2018-2023)
  • TABLE 52 LATAM IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2017)
  • TABLE 53 LATAM IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2018-2023)
  • TABLE 54 LATAM IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013-2017)
  • TABLE 55 LATAM IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2018-2023)
  • TABLE 56 MEA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2017)
  • TABLE 57 MEA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2018-2023)
  • TABLE 58 MEA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2017)
  • TABLE 59 MEA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2018-2023)
  • TABLE 60 MEA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013-2017)
  • TABLE 61 MEA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2018-2023)
  • TABLE 62 ELI LILLY AND COMPANY - AT A GLANCE
  • TABLE 63 ELI LILLY AND COMPANY - KEY FINANCIAL SUMMARY
  • TABLE 64 SANOFI - AT A GLANCE
  • TABLE 65 SANOFI - KEY FINANCIAL SUMMARY
  • TABLE 66 NOVARTIS AG - AT A GLANCE
  • TABLE 67 NOVARTIS AG - KEY FINANCIAL SUMMARY
  • TABLE 68 ABBVIE INC. - AT A GLANCE
  • TABLE 69 ABBVIE INC. - KEY FINANCIAL SUMMARY
  • TABLE 70 F. HOFFMANN-LA ROCHE LTD. - AT A GLANCE
  • TABLE 71 F. HOFFMANN-LA ROCHE LTD. - KEY FINANCIAL SUMMARY
  • TABLE 72 ASTRAZENECA PLC - AT A GLANCE
  • TABLE 73 ASTRAZENECA PLC - KEY FINANCIAL SUMMARY
  • TABLE 74 MERCK & CO. INC. - AT A GLANCE
  • TABLE 75 MERCK & CO. INC. - KEY FINANCIAL SUMMARY
  • TABLE 76 GLAXOSMITHKLINE PLC - AT A GLANCE
  • TABLE 77 GLAXOSMITHKLINE PLC - KEY FINANCIAL SUMMARY
  • TABLE 78 BRISTOL-MYERS SQUIBB COMPANY - AT A GLANCE
  • TABLE 79 BRISTOL-MYERS SQUIBB COMPANY - KEY FINANCIAL SUMMARY
  • TABLE 80 AMGEN INC. - AT A GLANCE
  • TABLE 81 AMGEN INC. - KEY FINANCIAL SUMMARY
  • TABLE 82 C. H. BOEHRINGER SOHN AG & CO. KG - AT A GLANCE
  • TABLE 83 C. H. BOEHRINGER SOHN AG & CO. KG - KEY FINANCIAL SUMMARY
  • TABLE 84 CELGENE CORPORATION - AT A GLANCE
  • TABLE 85 CELGENE CORPORATION - KEY FINANCIAL SUMMARY
  • TABLE 86 JOHNSON & JOHNSON - AT A GLANCE
  • TABLE 87 JOHNSON & JOHNSON - KEY FINANCIAL SUMMARY
  • TABLE 88 TAKEDA PHARMACEUTICAL COMPANY LIMITED - AT A GLANCE
  • TABLE 89 TAKEDA PHARMACEUTICAL COMPANY LIMITED - KEY FINANCIAL SUMMARY
  • TABLE 90 PFIZER INC. - AT A GLANCE
  • TABLE 91 PFIZER INC. - KEY FINANCIAL SUMMARY

List of Figures

  • FIG 1 RESEARCH SCOPE
  • FIG 2 RESEARCH METHODOLOGY
  • FIG 3 REGIONAL SPLIT OF PRIMARY AND SECONDARY RESEARCH
  • FIG 4 BREAKDOWN OF PRIMARY RESEARCH BY REGION
  • FIG 5 BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT
  • FIG 6 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE
  • FIG 7 DATA TRIANGULATION APPROACH
  • FIG 8 GLOBAL IMMUNOTHERAPY DRUGS MARKET SUMMARY
  • FIG 9 PREVALENCE OF MULTIPLE SCLEROSIS PER 100,000 PEOPLE IN EUROPEAN COUNTRIES (2015)
  • FIG 10 REIMBURSEMENT STATUS OF CANCER MEDICINES LAUNCHED DURING 2011-2015, IN SOME MAJOR COUNTRIES
  • FIG 11 IMPACT ANALYSIS OF DRIVERS ON MARKET FORECAST
  • FIG 12 IMPACT ANALYSIS OF DRIVERS ON MARKET FORECAST
  • FIG 13 BARGAINING POWER OF BUYERS
  • FIG 14 BARGAINING POWER OF SUPPLIERS
  • FIG 15 INTENSITY OF RIVALRY
  • FIG 16 THREAT OF NEW ENTRANTS
  • FIG 17 THREAT OF SUBSTITUTES
  • FIG 18 SNAPSHOT OF GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE, (2017)
  • FIG 19 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $B (2013-2023)
  • FIG 20 GLOBAL IMMUNOTHERAPY CHECKPOINT INHIBITORS MARKET, BY BRAND, $B (2013-2023)
  • FIG 21 GLOBAL IMMUNOTHERAPY VACCINES MARKET, BY TYPE, $B (2013-2023)
  • FIG 22 GLOBAL IMMUNOTHERAPY VACCINES MARKET, BY BRAND, $B (2013-2023)
  • FIG 23 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2023)
  • FIG 24 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2023)
  • FIG 25 WORLDWIDE MAJOR MARKETS FOR IMMUNOTHERAPY DRUGS
  • FIG 26 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
  • FIG 27 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2023)
  • FIG 28 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2023)
  • FIG 29 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013-2023)
  • FIG 30 EUROPE IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
  • FIG 31 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2023)
  • FIG 32 HEALTHCARE DATA FOR SPAIN, DENMARK AND AUSTRIA (FOR THE YEARS 2000, 2008 & 2015)
  • FIG 33 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2023)
  • FIG 34 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013-2023)
  • FIG 35 APAC IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
  • FIG 36 APAC IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2023)
  • FIG 37 APAC IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2023)
  • FIG 38 APAC IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013-2023)
  • FIG 39 LATAM IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
  • FIG 40 LATAM IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2023)
  • FIG 41 LATAM IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2023)
  • FIG 42 LATAM IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013-2023)
  • FIG 43 MEA IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
  • FIG 44 MEA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2023)
  • FIG 45 MEA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2023)
  • FIG 46 MEA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013-2023)
  • FIG 47 PRODUCT BENCHMARKING OF KEY PLAYERS
  • FIG 48 ELI LILLY AND COMPANY - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
  • FIG 49 SANOFI - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
  • FIG 50 NOVARTIS AG - REVENUE SPLIT BY DIVISION AND GEOGRAPHY (2017)
  • FIG 51 ABBVIE INC. - REVENUE SPLIT BY PRODUCT SALES AND GEOGRAPHY (2017)
  • FIG 52 F. HOFFMANN-LA ROCHE LTD. - REVENUE SPLIT BY DIVISION AND GEOGRAPHY (2017)
  • FIG 53 ASTRAZENECA PLC - REVENUE SPLIT BY THERAPY AREA AND GEOGRAPHY (2017)
  • FIG 54 MERCK & CO. INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
  • FIG 55 GLAXOSMITHKLINE PLC - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
  • FIG 56 BRISTOL-MYERS SQUIBB COMPANY - REVENUE SPLIT BY PRODUCT CATEGORY AND GEOGRAPHY (2017)
  • FIG 57 AMGEN INC. - REVENUE SPLIT BY PRODUCT SALES AND GEOGRAPHY (2017)
  • FIG 58 C. H. BOEHRINGER SOHN AG & CO. KG - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
  • FIG 59 CELGENE CORPORATION - REVENUE SPLIT BY PRODUCT SALES AND GEOGRAPHY (2017)
  • FIG 60 JOHNSON & JOHNSON - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
  • FIG 61 TAKEDA PHARMACEUTICAL COMPANY LIMITED - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2016)
  • FIG 62 PFIZER INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
目次

Immunotherapy drugs market is forecasted to attain a size of $227.6 billion by 2023, with the thriving demand and increase in the development of monoclonal antibodies (mAbs), increasing prevalence of chronic diseases, and growing implementation of target therapy, the market is expected to progress significantly in the coming years.

Based on type, the immunotherapy drugs market has been categorized into checkpoint inhibitors and vaccines. Among these two, the checkpoint inhibitors category generated higher revenue in the historical period, and is expected to generate more than $100.0 billion revenue by 2023. Increasing development of mAbs, and rise in the adoption of chimeric antigen receptor (CAR) T-cell therapy are the major factors contributing to the larger share of this category.

Vaccines are further sub-categorized on the basis of type and brand. The two types of vaccines available in the immunotherapy drugs market are preventive and therapeutic vaccines. Among these, preventive vaccines held a larger share in the market. Among the various brand of vaccines available, Prevnar/Prevenar 13 is one of the bestseller vaccines brands and generated the highest revenue of $5.6 billion in the market, in 2017.

Immunotherapy drugs are majorly used for the treatment of cancer, autoimmune and inflammatory diseases, and infectious diseases. Cancer held the largest share in the immunotherapy drugs market for therapy area, in 2017. This can be ascribed to the increasing prevalence of cancer across the globe.

On the basis of end user, the immunotherapy drugs market has been categorized into hospitals and clinics, and individuals. Of these, hospitals and clinics are expected to demonstrate faster growth, at a CAGR of 14.0% during the forecast period. This can be attributed to the increasing patient base in hospitals and clinics, which leads to high requirement of immunotherapy drugs in this end-user category.

The APAC immunotherapy drugs market is expected to observe the fastest growth, at a CAGR of 14.3% during the forecast period, mainly on account of increasing healthcare expenditure for the improvement of healthcare infrastructure and growing research and development (R&D) activities in the region.

The players in the immunotherapy drugs industry are enhancing their product portfolio through product launches and also have received approvals from government organizations for its application. For instance, in September 2018, Sanofi received approval for Libyato for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC, who are not candidates for curative surgery or curative radiation.

Likewise, in September 2018, AstraZeneca plc received the U.S. Food and Drug Administration (USFDA) approval for Lumoxiti (moxetumomab pasudotox-tdfk). AstraZeneca plc developed Lumoxiti together with MedImmune LLC, for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (HCL), who have received at least two prior systemic therapies, including purine nucleoside analog treatment.

F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck & Co. Inc., GlaxoSmithKline plc, Novartis International AG, Johnson & Johnson, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Medigene AG, C. H. Boehringer Sohn AG & Co. KG, Takeda Pharmaceutical Company Limited, Celgene Corporation, and Pfizer Inc. are other key players present in the immunotherapy drugs market.

The scope of study also includes the epidemiology coverage for cancer, autoimmune and inflammatory diseases, and infectious diseases; pricing and reimbursement scenario for immunotherapy drugs; research and funding initiatives for immunotherapy drugs; and list of immunotherapy drugs in the pipeline of the key market players.

Table of Content

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Market Definition
  • 1.3 Research Scope
    • 1.3.1 Market Segmentation by Type
    • 1.3.2 Market Segmentation by Therapy Area
    • 1.3.3 Market Segmentation by End User
    • 1.3.4 Market Segmentation by Geography
    • 1.3.5 Analysis Period
    • 1.3.6 Market Data Reporting Unit
      • 1.3.6.1 Value
  • 1.4 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
  • 2.2 Primary Research
    • 2.2.1 Breakdown of Primary Research Respondents
      • 2.2.1.1 By region
      • 2.2.1.2 By industry participant
      • 2.2.1.3 By company type
  • 2.3 Market Size Estimation
  • 2.4 Data Triangulation
  • 2.5 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Industry Insights

  • 4.1 Epidemiology Analysis
    • 4.1.1 Cancer
    • 4.1.2 Autoimmune and Inflammatory Diseases
      • 4.1.2.1 Autoimmune diseases
      • 4.1.2.2 Inflammatory diseases
    • 4.1.3 Infectious Diseases
  • 4.2 Pricing and Reimbursement Scenario for Immunotherapy Drugs
    • 4.2.1 Global
    • 4.2.2 Europe
      • 4.2.2.1 U.K.
      • 4.2.2.2 Belgium
      • 4.2.2.3 France
      • 4.2.2.4 Italy
      • 4.2.2.5 Spain
    • 4.2.3 North America
      • 4.2.3.1 U.S.
    • 4.2.4 APAC
      • 4.2.4.1 Japan
      • 4.2.4.2 China
      • 4.2.4.3 Australia
  • 4.3 Research and Funding Initiatives for Immunotherapy Drugs
  • 4.4 List of Pipeline Drugs
    • 4.4.1 Sanofi
    • 4.4.2 Pfizer Inc.
    • 4.4.3 Novartis AG
    • 4.4.4 Merck & Co. Inc.
    • 4.4.5 Johnson & Johnson
    • 4.4.6 GlaxoSmithKline plc
    • 4.4.7 F. Hoffman-La Roche Ltd.
    • 4.4.8 Eli Lilly and Company
    • 4.4.9 Celgene Corporation
    • 4.4.10 C. H. Boehringer Sohn AG & Co. KG
    • 4.4.11 Bristol-Myers Squibb Company
    • 4.4.12 AstraZeneca PLC
    • 4.4.13 AbbVie Inc.
  • 4.5 Treatment Protocols and Line of Therapies
    • 4.5.1 First-Line Therapy for Treating Cancer
    • 4.5.2 Second-Line Therapy for Treating Cancer
    • 4.5.3 Other Treatments
      • 4.5.3.1 Targeted therapy
      • 4.5.3.2 Hormone therapy

Chapter 5. Introduction

  • 5.1 Definition of Market Segments
    • 5.1.1 By Type
      • 5.1.1.1 Checkpoint inhibitors
        • 5.1.1.1.1 By brand
        • 5.1.1.1.1.1 Humira
        • 5.1.1.1.1.2 Rituxan/MabThera
        • 5.1.1.1.1.3 Herceptin
        • 5.1.1.1.1.4 Remicade
        • 5.1.1.1.1.5 Enbrel
        • 5.1.1.1.1.6 Others
      • 5.1.1.2 Vaccines
        • 5.1.1.2.1 By type
        • 5.1.1.2.1.1 Preventive vaccines
        • 5.1.1.2.1.2 Therapeutic vaccines
        • 5.1.1.2.2 By brand
        • 5.1.1.2.2.1 Prevnar/ Prevenar 13
        • 5.1.1.2.2.2 Gardasil
        • 5.1.1.2.2.3 ProQuad
        • 5.1.1.2.2.4 Rotarix
        • 5.1.1.2.2.5 Others
    • 5.1.2 By Therapy Area
      • 5.1.2.1 Cancer
      • 5.1.2.2 Autoimmune and inflammatory diseases
      • 5.1.2.3 Infectious diseases
    • 5.1.3 By End User
      • 5.1.3.1 Hospitals and clinics
      • 5.1.3.2 Individuals
  • 5.2 Market Dynamics
    • 5.2.1 Drivers
      • 5.2.1.1 Surge in the prevalence of chronic diseases
      • 5.2.1.2 Thriving demand and development of mAbs
      • 5.2.1.3 Rise in the implementation of target therapy
      • 5.2.1.4 Increasing availability of biosimilars
      • 5.2.1.5 Impact analysis of drivers on market forecast
    • 5.2.2 Restraints
      • 5.2.2.1 High cost of immunotherapy treatment
      • 5.2.2.2 Impact analysis of restraints on market forecast
  • 5.3 Porter's Five Forces Analysis

Chapter 6. Global Market Size and Forecast

  • 6.1 By Type
    • 6.1.1 Checkpoint Inhibitors Market, by Brand
    • 6.1.2 Vaccines Market, by Type
    • 6.1.3 Vaccines Market, by Brand
  • 6.2 By Therapy Area
  • 6.3 By End User
  • 6.4 By Region

Chapter 7. North America Market Size and Forecast

  • 7.1 By Therapy Area
  • 7.2 By End User
  • 7.3 By Country

Chapter 8. Europe Market Size and Forecast

  • 8.1 By Therapy Area
  • 8.2 By End User
  • 8.3 By Country

Chapter 9. APAC Market Size and Forecast

  • 9.1 By Therapy Area
  • 9.2 By End User
  • 9.3 By Country

Chapter 10. LATAM Market Size and Forecast

  • 10.1 By Therapy Area
  • 10.2 By End User
  • 10.3 By Country

Chapter 11. MEA Market Size and Forecast

  • 11.1 By Therapy Area
  • 11.2 By End User
  • 11.3 By Country

Chapter 12. Competitive Landscape

  • 12.1 Product Benchmarking of Key Players
  • 12.2 Global Strategic Developments of Key Players
    • 12.2.1 Mergers and Acquisitions
    • 12.2.2 Product Launches and Approvals
    • 12.2.3 Collaborations, Partnerships and Agreements
    • 12.2.4 Other Developments

Chapter 13. Company Profiles

  • 13.1 Eli Lilly and Company
    • 13.1.1 Business Overview
    • 13.1.2 Product and Service Offerings
      • 13.1.2.1 Marketed products
      • 13.1.2.2 Pipeline products
    • 13.1.3 Key Financial Summary
  • 13.2 Sanofi
    • 13.2.1 Business Overview
    • 13.2.2 Product and Service Offerings
      • 13.2.2.1 Marketed products
      • 13.2.2.2 Pipeline products
    • 13.2.3 Key Financial Summary
  • 13.3 Novartis AG
    • 13.3.1 Business Overview
    • 13.3.2 Product and Service Offerings
      • 13.3.2.1 Marketed products
      • 13.3.2.2 Pipeline products
    • 13.3.3 Key Financial Summary
  • 13.4 AbbVie Inc.
    • 13.4.1 Business Overview
    • 13.4.2 Product and Service Offerings
      • 13.4.2.1 Marketed products
      • 13.4.2.2 Pipeline products
    • 13.4.3 Key Financial Summary
  • 13.5 F. Hoffmann-La Roche Ltd.
    • 13.5.1 Business Overview
    • 13.5.2 Product and Service Offerings
      • 13.5.2.1 Marketed products
      • 13.5.2.2 Pipeline products
    • 13.5.3 Key Financial Summary
  • 13.6 AstraZeneca PLC
    • 13.6.1 Business Overview
    • 13.6.2 Product and Service Offerings
      • 13.6.2.1 Marketed products
      • 13.6.2.2 Pipeline products
    • 13.6.3 Key Financial Summary
  • 13.7 Merck & Co. Inc.
    • 13.7.1 Business Overview
    • 13.7.2 Product and Service Offerings
      • 13.7.2.1 Marketed products
      • 13.7.2.2 Pipeline products
    • 13.7.3 Key Financial Summary
  • 13.8 GlaxoSmithKline plc
    • 13.8.1 Business Overview
    • 13.8.2 Product and Service Offerings
      • 13.8.2.1 Marketed products
      • 13.8.2.2 Pipeline products
    • 13.8.3 Key Financial Summary
  • 13.9 Bristol-Myers Squibb Company
    • 13.9.1 Business Overview
    • 13.9.2 Product and Service Offerings
      • 13.9.2.1 Marketed products
      • 13.9.2.2 Pipeline products
    • 13.9.3 Key Financial Summary
  • 13.10 Amgen Inc.
    • 13.10.1 Business Overview
    • 13.10.2 Product and Service Offerings
      • 13.10.2.1 Marketed products
      • 13.10.2.2 Pipeline products
    • 13.10.3 Key Financial Summary
  • 13.11 C. H. Boehringer Sohn AG & Co. KG
    • 13.11.1 Business Overview
    • 13.11.2 Product and Service Offerings
      • 13.11.2.1 Marketed products
      • 13.11.2.2 Pipeline products
    • 13.11.3 Key Financial Summary
  • 13.12 Celgene Corporation
    • 13.12.1 Business Overview
    • 13.12.2 Product and Service Offerings
      • 13.12.2.1 Marketed products
      • 13.12.2.2 Pipeline products
    • 13.12.3 Key Financial Summary
  • 13.13 Johnson & Johnson
    • 13.13.1 Business Overview
    • 13.13.2 Product and Service Offerings
      • 13.13.2.1 Marketed products
      • 13.13.2.2 Pipeline products
    • 13.13.3 Key Financial Summary
  • 13.14 Takeda Pharmaceutical Company Limited
    • 13.14.1 Business Overview
    • 13.14.2 Product and Service Offerings
      • 13.14.2.1 Marketed products
      • 13.14.2.2 Pipeline products
    • 13.14.3 Key Financial Summary
  • 13.15 Pfizer Inc.
    • 13.15.1 Business Overview
    • 13.15.2 Product and Service Offerings
      • 13.15.2.1 Marketed products
      • 13.15.2.2 Pipeline products:
    • 13.15.3 Key Financial Summary

Chapter 14. Appendix

  • 14.1 Abbreviations
  • 14.2 Sources and References
  • 14.3 Related Reports